Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

STEROID-THERAPY IN SEVERE VIRAL-HEPATITIS - DOUBLE-BLIND, RANDOMIZED TRIAL OF METHYL-PREDNISOLONE VERSUS PLACEBO NEW ENGLAND JOURNAL OF MEDICINE Gregory, P. B., Knauer, C. M., Kempson, R. L., Miller, R. 1976; 294 (13): 681-687

Abstract

The efficacy of corticosteroid therapy in severe viral hepatitis has never been demonstrated in a controlled clinical trial. For this reason, patients with severe viral hepatitis were randomly assigned to methyl-prednisolone or placebo treatment groups. The two groups were comparable in clinical findings, laboratory results and the presence of bridging necrosis on liver biopsy. Seven of the 14 patients assigned to methyl-prednisolone and two of the 15 assigned to placebo died during the 16-week study period. Although the apparent excess mortality in the steroid-treated patients is not quite statistically significant (P = 0.08), the trend persists when only patients positive for hepatitis B surface antigen (P = 0.04) are analyzed separately. Methyl-prednisolone does not enhance survival in patients with severe viral hepatitis, and it may be detrimental.

View details for Web of Science ID A1976BK23400001

View details for PubMedID 765822